Extraction-Free, Real-Time PCR Workflow with Capacity of Up to 6,000 Tests per Day Easy-to-Administer Saliva Test Would Eliminate Need for Invasive Nasopharyngeal Swab High-Throughput Assay Developed in Collaboration with Washington University School of Medicine SOUTH SAN FRANCISCO, Calif.

Study Suggests That Type I IFN Deficiency in the Blood Could Help Define a High-Risk Population SOUTH SAN FRANCISCO, Calif. , May 19, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health

SOUTH SAN FRANCISCO, Calif. , May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite , President and Chief Executive Officer, and Vikram

First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for Ultrahigh-Throughput COVID-19 Tests on the BioMark platform Maxpar Direct Immune Profiling Assay powering large

Custom Projects and Consultation from Experimental Panel Design to Data Analysis              Providing Instrument Access Prior to Purchase Decision and Much‑Needed Capacity for Customers Affected by COVID-19 Related Laboratory Closures              New Collaboration via Therapeutic Insights

Expediting Treatment of COVID-19 Patients and Enhancing Testing Resources for Caregivers in Oklahoma Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents SOUTH SAN FRANCISCO, Calif. , April 23, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation 

SOUTH SAN FRANCISCO, Calif. , April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2020 financial results on Thursday,

SOUTH SAN FRANCISCO, Calif. , April 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today provided an update on the impact of the COVID-19 pandemic on its business and

SOUTH SAN FRANCISCO, Calif. , April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm ® CyTOF ® technology was used in a clinical study

Speed and scale of Fluidigm microfluidics technology to facilitate early-stage host monitoring for COVID-19 SOUTH SAN FRANCISCO, Calif. , March 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through